Core Viewpoint - Fosun Pharma's medical device and diagnostic business experienced a revenue decline in 2024, attributed to decreased sales of COVID-19 related products, with a reported revenue of RMB 4.323 billion, down 1.53% year-on-year [2][3] Financial Performance - As of April 3, 2025, Fosun Pharma's stock closed at RMB 25.51, with a slight increase of 0.2% and a trading volume of 166,900 shares, amounting to a total transaction value of RMB 426 million [1] - The company reported a segment loss of RMB 112 million in its medical device and diagnostic business for 2024, which is a year-on-year increase in loss of RMB 14 million [2] - The total amount repurchased for A-shares reached approximately RMB 39.99 million, while H-shares amounted to about HKD 22.91 million as of March 31, 2025 [7] Business Development - Fosun Pharma's CAR-T cell therapy product, Yikaida, was the first approved CAR-T therapy in China, with two indications approved and a third indication currently in bridging clinical trials [3] - The company aims to reduce the cost of CAR-T therapies to below RMB 100,000 by 2028 through advancements in technology and production processes [4] - Multiple CAR-T projects targeting BCMA/CD19 are in preclinical research stages, indicating ongoing innovation in the field [3] Market Activity - On the trading day, the net inflow of main funds was RMB 16.16 million, accounting for 3.8% of the total transaction value, while retail investors saw a net outflow of RMB 20.11 million [6] - The company has been actively repurchasing shares, with a plan to buy back between RMB 300 million to 600 million worth of shares from January 23, 2025, to July 21, 2025 [7]